Recombinant Therapeutic Antibodies and Proteins Market - Size, Share, trends, and Forecast, 2022 - 2028

Recombinant Therapeutic Antibodies and Proteins Market - Size, Share, trends, and Forecast, 2022 - 2028

Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies are highly successful and experience unparalleled growth potential in terms of their efficacy.
Market Dynamics
Recombinant therapeutic proteins and antibodies have gained high traction in clinical applications. Due to development of antibody-based therapeutics, mammalian expression systems have experienced a major boost and microbial expression systems continue to be widely used in industries, which in turn will fuel growth of the market. However, variations in production methods of therapeutic antibodies can lead to differences in their structure, based on the selection of recombinant procedure. Most protein therapeutics available in the market are recombinant and majority of them are in clinical trials for therapy of immune disorders, cancers, infections, and other diseases. Various engineered proteins, including multi-specific fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule drugs, and proteins with optimized pharmacokinetics are under development.
Key features of the study:

This report provides in-depth analysis of recombinant therapeutic antibodies and proteins market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global recombinant therapeutic antibodies and proteins market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans
Key companies covered as a part of this study include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global recombinant therapeutic antibodies and proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the recombinant therapeutic antibodies and proteins market

Detailed Segmentation:

Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Geography:

North America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

U.S.
Canada

Latin America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

GCC
Israel
Rest of Middle East

Africa Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Diseases
Others

By Country:

North Africa
South Africa
Central Africa

Company Profiles

Abbott Laboratories*

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Amgen Inc.
Biogen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche
Johnson and Johnson
Merck & Co.
Novo Nordisk
Pfizer, Inc.
Sanofi S.A.

“*” marked represents similar segmentation in other categories in the respective section.